5/16/2023 7:47:30 AM
Soligenix Announces European Patent Grant For Use Of Dusquetide In Oral Mucositis
5/11/2023 7:32:40 AM
Soligenix Updates On FDA Meeting Outcome Expected Next Month
5/5/2023 9:06:31 AM
Soligenix Announces Pricing Of $8.5 Mln Public Offering
5/4/2023 7:44:09 AM
Soligenix Announces Positive Results From Compatibility Study Of HyBryte In Treatment Of Cutaneous T-Cell Lymphoma
5/1/2023 7:37:07 AM
Soligenix Reaches Deal With Silk Road For Rights To Topical Pentoxifylline Designed To Treat Behçet's Disease
4/5/2023 7:36:53 AM
Soligenix Gets USAN Approval For Hypericin Sodium As Nonproprietary Name For Novel Active Ingredient In HyBryte, SGX302
4/3/2023 7:40:15 AM
Soligenix Announces Scheduling Of Type A Meeting With FDA For HyBryte NDA In The Treatment Of Cutaneous T-Cell Lymphoma
2/14/2023 7:33:30 AM
Soligenix Receives Refusal To File Letter From DA For HyBryte NDA In Treatment Of Cutaneous T-Cell Lymphoma
2/9/2023 7:40:36 AM
Soligenix Intends To Effect Reverse Stock Split Of Stock At A Ratio Of 1 Post-split Share For Every 15 Pre-split Shares
12/20/2022 7:36:36 AM
Soligenix Announces Publication Showing Positive Correlates Of Protection With RiVax In Non-Human Primate Survival
12/15/2022 7:34:13 AM
Soligenix Submits NDA To The FDA For HyBryte In The Treatment Of Cutaneous T-cell Lymphoma
11/10/2022 7:40:16 AM
Soligenix Q3 Net Loss $3.3 Mln Or $0.08/shr Vs Loss $3.6 Mln Or $0.09/shr Prior Year